- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03559699
A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)
December 14, 2021 updated by: Agios Pharmaceuticals, Inc.
An Open-Label Study To Evaluate the Efficacy and Safety of AG-348 in Regularly Transfused Adult Subjects With Pyruvate Kinase (PK) Deficiency
Study AG348-C-007 was a multicenter study designed to evaluate the efficacy and safety of treatment with AG-348 in a minimum of 20, with up to 40, participants with pyruvate kinase (PK) deficiency, who were regularly receiving blood transfusions.
The study was composed of two parts.
During Part 1, Dose Optimization Period, participants started on a dose of 5 mg AG-348 administered twice daily.
Over the course of Part 1 each participant's dose of AG-348 was sequentially increased to 20 mg twice a day, followed by 50 mg twice a day depending on their tolerance.
During Part 2, Fixed-Dose Period, participants received AG-348 at their optimized dose from Part 1.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Toronto, Canada, M5G 2C4
- Toronto General Hospital, University Health Network
-
-
-
-
-
Herlev, Denmark, 2730
- University of Copenhagen, Herlev Hospital
-
-
-
-
-
Créteil, France, 94010
- Hôpital Universitaire Henri Mondor
-
Marseille, Cedex 5, France, 13385
- Hopital de la Timone
-
-
-
-
-
Dublin, Ireland
- St James's Hospital Department of Haematology
-
-
-
-
-
Milano, Italy, 20122
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
-
Napoli, Italy, 80138
- AOU Policlinico, Università della Campania "Luigi Vanvitelli"
-
Napoli, Italy, 80131
- AORN Cardarelli
-
Napoli, Italy, 80131
- Ospedale Galliera
-
-
-
-
-
Utrecht, Netherlands, 3584
- Universitair Medisch Centrum Utrecht
-
-
-
-
-
Bangkok, Thailand, 10700
- Department of Paediatrics and Thalassaemia Center, Faculty of Medicine Siriraj Hospital, Mahidol University
-
-
-
-
-
Cambridge, United Kingdom, CB2 0QQ
- Addenbrooke's Hospital
-
London, United Kingdom, WC1E 6BT
- University College London
-
London, United Kingdom, W12 0NN
- Imperial College Healthcare NHS Trust, Hammersmith Hospital
-
Manchester, United Kingdom, M13 9WL
- Manchester Royal Infirmary
-
-
-
-
California
-
Oakland, California, United States, 94609
- UCSF Benioff Children's Hospital
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Massachusetts General Hospital
-
-
Washington
-
Seattle, Washington, United States, 98109
- Seattle Cancer Care Alliance
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Informed consent;
- Male or female, aged 18 or older;
- Presence of at least 2 mutant alleles in the Pyruvate Kinase Liver and RBC (PKLR) gene, of which at least 1 is a missense mutation;
- History of a minimum of 6 transfusion episodes in the 52-week period prior to date of informed consent;
- Complete records of transfusion history for the 52 weeks prior to the date of informed consent, including all transfusion dates, number of blood units transfused for all the transfusions, and Hb concentrations within 1 week prior to transfusion for at least 80% of the transfusions;
- Have received at least 0.8 mg of oral folic acid daily for at least 21 days prior to the first dose of study drug, to be continued daily during study participation;
- Have adequate organ function;
- Negative serum pregnancy test for women of reproductive potential;
- For women of reproductive potential as well as fertile men and their partners who are women of reproductive potential: be abstinent or agree to use 2 forms of contraception, 1 of which must be considered highly effective, from the time of giving informed consent, during the study, and for 28 days following the last dose of AG-348;
- Willing to comply with all study procedures, in particular the individual transfusion trigger (TT) calculated based on 52 weeks of transfusion history, for the duration of the study.
Exclusion Criteria:
- Homozygous for the R479H mutation or have 2 non-missense mutations, without the presence of another missense mutation, in the PKLR gene;
- Significant medical condition that confers an unacceptable risk to participate in the study, and/or that could confound the interpretation of the study data;
- History of transfusions occurring on average more frequently than once every 3 weeks during the 52 weeks prior to date of informed consent;
- Splenectomy scheduled during the study treatment period or have undergone splenectomy within 12 months prior to signing informed consent;
- Currently enrolled in another therapeutic clinical trial. Prior participation in the PK Deficiency Natural History Study (NHS) (NCT02053480) or PK Deficiency Registry is permitted;
- Exposure to any investigational drug, device, or procedure within 3 months prior to the first dose of study drug;
- Prior bone marrow or stem cell transplant;
- Currently pregnant or breastfeeding;
- History of major surgery within 6 months of signing informed consent;
- Currently receiving medications that are strong inhibitors of CYP3A4, strong inducers of CYP3A4, strong inhibitors of P-glycoprotein (P-gp), or digoxin (a P-gp sensitive substrate medication) that have not been stopped for a duration of at least 5 days or 5 times their half-lives (whichever is longer) prior to start of study drug;
- Currently receiving hematopoietic stimulating agents (eg, erythropoietins [EPOs], granulocyte colony stimulating factors, thrombopoietins) that have not been stopped for a duration of at least 28 days prior to the first dose of study drug;
- History of allergy to sulfonamides if characterized by acute hemolytic anemia, drug induced liver injury, anaphylaxis, rash of erythema multiforme type or Stevens-Johnson syndrome, cholestatic hepatitis or other serious clinical manifestations;
- Allergy to AG-348 or its excipients;
- Currently receiving anabolic steroids, including testosterone preparations, within 28 days prior to the first dose of study drug.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AG-348
Participants received AG-348 tablets, administered orally, at a starting dose of 5 milligrams (mg), twice daily (BID), followed by two sequential dose level increases to 20 mg and 50 mg BID, for a period of 16 weeks in Part 1.
This was followed by optimized dose BID, as determined by the investigator in Part 1, for a period of 24 weeks in Part 2.
|
Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance. Part 2 (Fixed Dose Period): Optimized dose determined in Part 1. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving a Reduction in Transfusion Burden in Part 2
Time Frame: From Part 2, Day 1 to Part 2 Week 24
|
Reduction in transfusion burden is defined as a ≥33% reduction in the number of RBC units transfused during the Fixed Dose Period standardized to 24 weeks compared with the historical transfusion burden standardized to 24 weeks (Standardized Control Period).
The on-study (Fixed Dose Period) transfusion burden was calculated as the total number of transfused RBC units received in the Fixed Dose Period standardized to 24 weeks.
|
From Part 2, Day 1 to Part 2 Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Annualized Number of RBC Units Transfused During the Study
Time Frame: Part 1 Day 1 to Part 2 Week 24
|
The annualized total number of RBC units transfused during the entire study (both Part 1 and Part 2) is reported.
It was calculated as the total number of RBC units transfused up to the end of Fixed Dose Period divided by the total number of days from the first dose date until the end date of Fixed Dose Period × 52.
|
Part 1 Day 1 to Part 2 Week 24
|
Number of Transfusion Episodes in Part 2
Time Frame: From Part 2 Day 1 to Part 2 Week 24
|
This is the number of transfusion episodes in Part 2. The number of transfusion episodes were standardized to 24 weeks.
Transfusions received over up to 3 consecutive days were counted as 1 episode.
|
From Part 2 Day 1 to Part 2 Week 24
|
Percentage of Transfusion-Free Participants in Part 2
Time Frame: From Part 2 Day 1 to Part 2 Week 24
|
Transfusion-free responders were the participants who were transfusion-free in Part 2.
|
From Part 2 Day 1 to Part 2 Week 24
|
Percentage of Participants Achieving Normal Hemoglobin (Hb) Concentrations in Part 2
Time Frame: From Part 2 Day 1 to Part 2 Week 24
|
This is the percentage of participants who achieved hemoglobin (Hb) concentrations in the normal range at least once, 8 weeks or more after a transfusion in Part 2.
|
From Part 2 Day 1 to Part 2 Week 24
|
Percentage of Participants With Adverse Events
Time Frame: Through 4 weeks after last dose (approximately Part 2, Week 31)
|
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study drug.
An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
|
Through 4 weeks after last dose (approximately Part 2, Week 31)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Experiencing an Adverse Event of Special Interest (AESI)
Time Frame: From Part 1 Day 1 to end of Part 2, including follow-up (Day 197)
|
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An AESI can be serious or non-serious.
|
From Part 1 Day 1 to end of Part 2, including follow-up (Day 197)
|
Bone Mineral Density Z-Score
Time Frame: Part 1, Day 1, Part 2, Day 1 and Part 2, Week 24
|
Part 1, Day 1, Part 2, Day 1 and Part 2, Week 24
|
|
Bone Mineral Density T-Score
Time Frame: Part 1, Day 1, Part 2, Day 1 and Part 2, Week 24
|
Part 1, Day 1, Part 2, Day 1 and Part 2, Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Rab MAE, Van Oirschot BA, Kosinski PA, Hixon J, Johnson K, Chubukov V, Dang L, Pasterkamp G, Van Straaten S, Van Solinge WW, Van Beers EJ, Kung C, Van Wijk R. AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes. Haematologica. 2021 Jan 1;106(1):238-249. doi: 10.3324/haematol.2019.238865.
- Glenthoj A, van Beers EJ, Al-Samkari H, Viprakasit V, Kuo KHM, Galacteros F, Chonat S, Porter J, Zagadailov E, Xu R, Oluyadi A, Hawkins P, Gheuens S, Beynon V, Barcellini W; ACTIVATE-T investigators. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial. Lancet Haematol. 2022 Oct;9(10):e724-e732. doi: 10.1016/S2352-3026(22)00214-9. Epub 2022 Aug 18.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 26, 2018
Primary Completion (Actual)
November 12, 2020
Study Completion (Actual)
November 12, 2020
Study Registration Dates
First Submitted
March 26, 2018
First Submitted That Met QC Criteria
June 6, 2018
First Posted (Actual)
June 18, 2018
Study Record Updates
Last Update Posted (Actual)
January 4, 2022
Last Update Submitted That Met QC Criteria
December 14, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AG348-C-007
- 2017-003803-22 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia, Hemolytic
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Novartis PharmaceuticalsRecruitingWarm Autoimmune Hemolytic Anemia (wAIHA)China, Japan, Spain, Singapore, France, Germany, Taiwan, United States, Italy, India, Malaysia, Argentina, Hungary, Israel, Australia, Thailand, United Kingdom, Romania
-
Annexon, Inc.CompletedWarm Autoimmune Hemolytic Anemia (wAIHA)United States
-
Eugene NikitinUnknownAIHA - Warm Autoimmune Hemolytic AnemiaRussian Federation
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
-
Alexion PharmaceuticalsTerminatedWarm Autoimmune Hemolytic AnemiaUnited States, Jordan
-
Institute of Hematology & Blood Diseases Hospital...RecruitingRefractory/Relapsed Autoimmune Hemolytic AnemiaChina
Clinical Trials on AG-348
-
Agios Pharmaceuticals, Inc.Completed
-
Agios Pharmaceuticals, Inc.CompletedHealthy VolunteersUnited States
-
Agios Pharmaceuticals, Inc.Completed
-
Agios Pharmaceuticals, Inc.CompletedHealthy | Japanese | Non-AsianUnited States
-
Agios Pharmaceuticals, Inc.Completed
-
Agios Pharmaceuticals, Inc.Completed
-
Agios Pharmaceuticals, Inc.Not yet recruitingSickle Cell Disease | Nephropathy
-
Agios Pharmaceuticals, Inc.Active, not recruitingTransfusion-dependent Alpha-Thalassemia | Transfusion-dependent Beta-ThalassemiaSpain, Taiwan, Thailand, United States, France, Canada, Malaysia, Germany, Netherlands, Bulgaria, United Kingdom, Turkey, Italy, Greece, United Arab Emirates, Brazil, Denmark, Lebanon, Saudi Arabia
-
Agios Pharmaceuticals, Inc.Active, not recruitingNon-Transfusion-dependent Alpha-Thalassemia | Non-Transfusion-dependent Beta-ThalassemiaSpain, Taiwan, Thailand, United Kingdom, Malaysia, United States, Netherlands, Bulgaria, Turkey, Italy, Canada, Brazil, France, United Arab Emirates, Denmark, Greece, Lebanon, Saudi Arabia
-
Agios Pharmaceuticals, Inc.CompletedModerate Hepatic ImpairmentUnited States